The neoadjuvant treatment of PD-1/PD-L1 inhibitor with chemotherapy produced satisfactory outcomes, indicating its potential as a promising neoadjuvant treatment for esophageal cancer. The gene discussed is PDCD1; the disease is esophageal cancer.